[{"orgOrder":0,"company":"SK Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"NBP2001","moa":"\nSARS-CoV-2 antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SK Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"SK Bioscience \/ AstraZeneca"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscience \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"International Vaccine Institute | GSK | Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ International Vaccine Institute | GSK | Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ International Vaccine Institute | GSK | Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Coalition for Epidemic Preparedness Innovations | International Vaccine Institute | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Coalition for Epidemic Preparedness Innovations | International Vaccine Institute | GSK","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Coalition for Epidemic Preparedness Innovations | International Vaccine Institute | GSK"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ GSK"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Coalition for Epidemic Preparedness Innovations | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Coalition for Epidemic Preparedness Innovations | GSK","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Coalition for Epidemic Preparedness Innovations | GSK"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0.14000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Expanded Collaboration","leadProduct":"Matrix-M","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ SK Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"SK Bioscience \/ SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"SK Bioscience \/ Sanofi"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Expanded Collaboration","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Novavax"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Novavax"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ SK Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"SK Bioscience \/ SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ SK Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"SK Bioscience \/ SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ SK Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"SK Bioscience \/ SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"GBP560","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SK Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GBP560","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GBP560","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"NBP615","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"PCV21 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Sanofi"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Doherty Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Quadrivalent Cell Culture-based Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Doherty Institute","highestDevelopmentStatusID":"2","companyTruncated":"SK Bioscience \/ Doherty Institute"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Vaxxas","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Typhoid Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"SK Bioscience \/ SK Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"SK Bioscience \/ SK Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Varicella Virus, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SK Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Sunflower Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Collaboration","leadProduct":"10-Valent HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ SK Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"SK Bioscience \/ SK Bioscience"}]

Find Clinical Drug Pipeline Developments & Deals by SK Bioscience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : The milestone marks the completion and demonstration of a tech transfer package for multiple HPV serotypes, first in a series tied to commercialization of the 10-valent HPV vaccine candidate.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          September 18, 2025

                          Lead Product(s) : 10-Valent HPV Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Sunflower Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : GBP560 is an mRNA-based vaccine candidate, which is being evaluated for the treatment of japanese encephalitis virus disease in adults.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 25, 2025

                          Lead Product(s) : GBP560

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : The collaboration aims to develop, license, and commercialize GBP410 (PCV21 vaccine) for both pediatric and adult populations, reaffirming their commitment to fighting pneumococcal disease.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : $52.0 million

                          December 23, 2024

                          Lead Product(s) : PCV21 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : GBP560 is a mRNA-based Japanese encephalitis vaccine candidate which is currently being evaluated for the treatment of japanese encephalitis virus disease.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 12, 2024

                          Lead Product(s) : GBP560

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : GBP560 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Encephalitis, Japanese.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          November 08, 2024

                          Lead Product(s) : GBP560

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Under the collaboration, SK bioscience will supply the antigen utilized by its typhoid conjugate vaccine, SKYTyhpoid to develop a novel vaccine-delivery device combination product using Vaxxas’ high-density microarray patch (HD-MAP) platform technology...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          August 24, 2023

                          Lead Product(s) : Typhoid Conjugate Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : Vaxxas

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Under the partnership, SK bioscience will explore potential future collaborations with Novavax such as utilizing the Novavax's adjuvant, Matrix-M for advancing protein-based vaccines inclding, Nuvaxovid (NVX-CoV2373) to prevent COVID-19.

                          Product Name : Nuvaxovid

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          August 08, 2023

                          Lead Product(s) : NVX-COV2373,COVID-19 Vaccine, Adjuvanted,Matrix-m1

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Novavax

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          08

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : GBP410 (21-Valent pneumococcal conjugate vaccine) vaccine that combines specific proteins with the polysaccharide capsule of Streptococcus pneumoniae, which causes pneumococcal diseases such as pneumonia and invasive pneumococcal disease.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          June 29, 2023

                          Lead Product(s) : 21-Valent Pneumococcal Conjugate Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Sanofi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : SK bioscience and the Doherty Institute will work to support and research in influenza biology, vaccines and antivirals. The program includes testing of anti-influenza compounds to identify new antivirals and development of quadrivalent cell culture-base...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 27, 2023

                          Lead Product(s) : Quadrivalent Cell Culture-based Influenza Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Sponsor : Doherty Institute

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Sky Zoster vaccine consists live attenuated varicella virus which is administered subcutaneously for the prevention of herpes zoster in adults 50 years of age or older.

                          Product Name : Sky Zoster

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          January 09, 2023

                          Lead Product(s) : Varicella Virus, Live Attenuated

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank